RegisterLogin

CDK9-IN-37

CAT: 0804-HY-173481Size: 1 EachDry Ice: NoHazardous: No
CAT#: HY-173481Size: 1 Each
Selected
PRICE
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CDK9-IN-37 (Compound 24) is a CDK9 inhibitor (EC50: 5.5 nM) with weak inhibition on other CDK isoforms, showing high selectivity. CDK9-IN-37 has significant antiproliferative activity against acute myeloid leukemia MOLM-13 cells (IC50: 0.034 μM) . CDK9-IN-37 inhibits the CDK9 signaling pathway, reduces the phosphorylation level of RNAP II CTD (Ser2), downregulates the anti-apoptotic protein McI-1, induces cell apoptosis, and arrests the cell cycle at the G2/M phase. CDK9-IN-37 can be used in the study of acute myeloid leukemia (AML) [1].
UNSPSC
12352005
Target
CDK
Related Pathways
Cell Cycle/DNA Damage
Field of Research
Cancer
Smiles
CCOC1=C(C(C2=CN=C(NC3=CC(C)=CC(S(=O)(C)=O)=C3)S2)=O)C=CC(F)=C1
Molecular Formula
C20H19FN2O4S2
Molecular Weight
434.50
References & Citations
[1]Chen S, et al. Design, synthesis and bio-evaluation of 2,5-disubstituted thiazole derivatives for potential treatment of acute myeloid leukemia through targeting CDK9. Bioorg Chem. 2025 Jun 15;160:108436.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK9

Related Products

CatalogName
HY-170442CDK2-IN-37
HY-153426CDK9-IN-23
HY-147131-01CDK9-IN-30
HY-155177CDK9-IN-27
HY-178039CDK9-IN-42
HY-149641CDK9-IN-29
HY-150562CDK9-IN-19
HY-156083CDK9-IN-28
HY-130850-01CDK9-IN-10
HY-168515CDK9-IN-35

Alternative Products

CatalogName
T207214-01CDK9-IN-37
521355-01CDK9
521354-01CDK9
310256-01CDK9
030082CDK9
E8ET1612-78Cdk9
MBS8534188-01Cdk9
030081CDK9
551242CDK9
CSB-CL005079HUCDK9

Popular Products